팝업레이어 알림

BeyondDx

  • We create New Paradigm for conquering Cancer

  • We are empowering lives providing deeper intricacies of diseases

  • Unlocking the power of precision medicine through comprehensive cancer profiling

About BeyondDx

BeyondDx is a precision medical company established in August 2023
with the goal of "Comprehensive Cancer Profiling with One Blood."

Our commitment to precision medicine goes beyond conventional approaches.
With UNIQUE iDXGate Solution, we unlock a wealth of invaluable insights,
enabling clinicians to delve deeper into the intricacies of each patient's condition.

view more

Our Strategy

We understand that each patient's journey with cancer is unique. That's why we have developed the groundbreaking iDXGate Solution,
a revolutionary technology that enables accurate analysis of various disease-related factors within a single blood sample.
By harnessing the power of this innovative solution, we empower clinicians to make well-informed decisions and provide patient-specific treatment plans.

Core Technology

iDXGate: UNIQUE BeyondDx Solution; Liquid biopsy-based multi-integrated analysis system

Pipeline

We are accelerating the development of innovative companion diagnostics to provide valuable insights to clinicians with our own platform technology.

view more

Biopharma Service

We collaborate closely with clinicians, researchers, and experts in the field to push the boundaries of what is possible.
We are helping pharmaceutical companies’ breakthrough for cancer therapeutics.

News Room

view more

News

Beyond DX Enters \'ForeCheck LC\' Market for Lung Cancer Screening

 https://www.yakup.com/news/index.html?mode=view&cat=12&nid=303512 Beyond DX Enters \'ForeCheck LC\' Market for Lung Cancer Screening Establishment of global manufacturing and quality management infrastructure for in vitro diagnostic medical devices \'ForeCheck LC\' clinical cruise in Korea to discuss development with local partner in China BeyondDX (CEO Sojin Jung), a multi-integrated analysis solution developer, announced on the 9th that it will enter the cancer screening market in earnest. Biond DX was recognized for meeting the GMP manufacturing standards for in vitro diagnostic medical device manufacturing and quality standards (GMP) after screening by the Korea Institute of Industrial Technology (KTL) and the Ministry of Food and Drug Safety for GMP manufacturing plants in Haan-ro 60, C-dong 1506, and 1507 in Gwangmyeong-si, Gyeonggi-do. In addition to the ISO 13485:2016 international standards acquired in August, facilities under the Enforcement Rules of the In Vitro Diagnostic Medical Device Act and production infrastructure suitable for domestic and international standards of manufacturing and quality control systems have been secured. Currently, the domestic clinical trial of \'ForeCheck LC\', a lung cancer screening in vitro diagnostic medical device based on Beyond DX\'s multi-integrated analysis solution, is cruising, and detailed development is being discussed with local partners embodied for the entry of China, the first global target country. According to Dr. Chen Wanqing of the Cancer Research Institute of the Academy of Chinese Medical Sciences, about 2,000 new lung cancer patients occur a day and about 1,700 die due to the aging population and severe air pollution in China. Accordingly, the Chinese government is implementing a policy to increase the five-year survival rate of cancer to 46.6% by 2030 (健康 国: 癌症防治 动实施 动, 2023-2030). Lung cancer is one of the low-survival cancers, but early detection is of paramount importance as the five-year survival rate reaches 80%. BeyondDX CEO Jung Sojin said, \"Beyond DX will show an example of establishing a commercialization partnership with ForeCheck LC\'s domestic and foreign permits based on proven production and development infrastructure,\" adding, \"We will expand to global markets such as Europe and the United States in the future.\"   

2024-12-10

News

BeyondDX Acquires International Standard Certification for \'ISO13485\' in Development of Multi-Integrated Analysis Solutions

https://www.thebionews.net/news/articleView.html?idxno=8225  BeyondDX Acquires International Standard Certification for \'ISO13485\' in Development of Multi-Integrated Analysis Solutions- In vitro diagnostic medical device research and development, manufacturing and quality management secured global level- \'ForeCheck LC\' to establish a bridgehead for domestic and global marketsDevelopment of Multi-integrated Analysis Solution Beyond DX (CEO Chung So-jin) announced on the 28th that it has first certified ISO 13485:2016 (Medical devices-Quality Management Systems for Regulatory Purpose), an international medical device quality management system certification.ISO 13485:2016 certification is an international standard certification that ensures that developers of in vitro diagnostic medical device manufacturing comply with the quality, safety and regulatory requirements of the product and, in particular, meets the required holding conditions for obtaining CE-IVDR certification, a European in vitro diagnostic device certification.The scope of BeyondDX\'s ISO 13485:2016 certification includes the design, development, manufacturing, sales, and service of immunodiagnostic reagent products in the in vitro diagnostic medical device system. Through this certification, BeyondDX is fully prepared to prove its product quality level and advance into the global market.Recently, regulations on in vitro diagnostic medical devices in the European Union have been continuously strengthened. In particular, it is essential to obtain European IVDR certification, so BeyondDX plans to preemptively acquire IVDR CE certification with domestic approval of \"Forecheck LC\", a medical device for early diagnosis of lung cancer, next year to expand exports in the European market.\"Based on our excellent technology and licensing capabilities, we will take a step forward in entering not only the domestic market but also the global market,\" said Jung So-jin, CEO of BeyondDX. 

2024-08-28

News

BeyondDX selects the Ministry of SMEs and Startups Deep Tech-TIPS...Get up to 1.7 billion won in support such as R&D

https://www.yakup.com/news/index.html?mode=view&cat=12&nid=295666BeyondDX selects the Ministry of SMEs and Startups Deep Tech-TIPS...Get up to 1.7 billion won in support such as R&D  T-cell-based immune environment profiling platform \'iDX Gate IO\' spurts commercialization  BeyondDx (CEO Jung Sojin), a multi-integrated analysis solution company, announced on the 17th that it has been selected as a private investment-led technology start-up support program \"Deep-Tech TIPS\" by the Ministry of SMEs and Startups.Deep Tech Tips is part of the Super Gap Startup 1000+ Project announced by the Ministry of SMEs and Startups to select and foster promising startups in 10 new industries, and it is a project that provides up to 1.7 billion won in commercialization and overseas marketing funds, including 1.5 billion won in R&D expenses to selected companies.Beyond DX is a liquid biopsy-based multi-integrated analysis solution development and diagnostic company that was founded in August 2023 and operates a unique pipeline and specialized technology for diseases with high socio-economic needs.The difference between BeyondDx and existing liquid biopsy companies is that it uses blood as an analyte, but it combines biomarkers such as protein biomarkers, blood tumor cells, blood tumor DNA, and T cells in order to establish an optimal diagnostic system.Among the diagnostic platforms it has, this Deep Tech tip targets iDX Gate IO (TCR profiling) solution based on T cells, and quickly profiles the characteristics of T cells (neo-antigen response TCR combination) that respond to cancer environments so that they can be applied to immune-based customized treatment.The key technologies that make up iDXGate IO are the Any-Hold IO System, which captures T cells that directly react with tumor antigens, and the Immunity clustering of Lymphocyte units by TCR (iCLUST), a TCR (T-cell receptor) pattern algorithm that can determine the reactivity of T cells following treatment.An official from BeyondDx said, \"iDXGate IO core technology is designed to predict and monitor the reactivity and side effects of treatment in real time, so it will be a technology that can overcome the limitations of immune environment profiling techniques, including existing immune companion diagnostics.\"Meanwhile, since November last year, BeyondDx has been conducting collaborative research using iDXGate IO with \'Senlang Bio\', a Chinese-based cell therapy company. With the selection of Deep Tech Tips, BeyondDx plans to accelerate its global expansion.  

2024-06-17

view more